Fig. 4From: Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter studyThe histogram of treatment-related adverse events rate of all grade and grade ≥ 3 in Chemo group and ICI Plus Chemo groupBack to article page